Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Charles Erlichman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1687-7080; OpenAlex author ID A5022511085. Sources: ClinicalTrials.gov.

Their work

Papers
5
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2007: 1 trial · 2008: none · 2009: 1 trial · 2010: none · 2011: none · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers

Papers 5

  1. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.011↗
  2. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Co-author DOI 10.1016/j.pan.2020.06.015↗
  3. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. Co-author DOI 10.1007/s10637-015-0246-2↗
  4. Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Co-author DOI 10.1097/cad.0000000000000009↗
  5. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreati… Co-author DOI 10.1002/cam4.27↗

Trials 2

  1. GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cann… Principal investigator NCT00878163↗
  2. Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer Principal investigator NCT00898781↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitesh J. Borad · 2 shared papers, 2020 · strength 0.16
  2. Thomas C. Smyrk · 2 shared papers, 2020 · strength 0.16
  3. Angela L. McCleary‐Wheeler · 2 shared papers, 2020 · strength 0.16
  4. Ryan Michael Carr · 2 shared papers, 2020 · strength 0.16
  5. Tanios Bekaii‐Saab · 2 shared papers, 2020 · strength 0.16
  6. Martín E. Fernández-Zapico · 2 shared papers, 2020 · strength 0.16
  7. George P. Kim · 2 shared papers, 2015–2020 · strength 0.14
  8. Robert R. McWilliams · 2 shared papers, 2015–2020 · strength 0.14
  9. Alex A. Adjei · 2 shared papers, 2013–2020 · strength 0.13
  10. Aminah Jatoi · 2 shared papers, 2013–2020 · strength 0.12
  11. Julian R. Molina · 2 shared papers, 2013–2020 · strength 0.12
  12. Rondell Patrell Graham · 1 shared paper, 2020 · strength 0.09
  13. George Kim · 1 shared paper, 2020 · strength 0.09
  14. Wilma Lingle · 1 shared paper, 2020 · strength 0.08
  15. Ezequiel J. Tolosa · 1 shared paper, 2020 · strength 0.08
  16. Axel F. Grothey · 1 shared paper, 2020 · strength 0.08
  17. Henry Clement Pitot · 1 shared paper, 2020 · strength 0.08
  18. Mien‐Chie Hung · 1 shared paper, 2020 · strength 0.08
  19. Katrina Sophia Pedersen · 1 shared paper, 2015 · strength 0.06
  20. Andrea Wang‐Gillam · 1 shared paper, 2015 · strength 0.06
  21. Aaron Scott Mansfield · 1 shared paper, 2013 · strength 0.04
  22. John J. Arcaroli · 1 shared paper, 2012 · strength 0.03
  23. Manuel M. Hidalgo · 1 shared paper, 2012 · strength 0.03
  24. Wells A. Messersmith · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.